Monday, September 07, 2020 7:59:16 PM
Tonix Pharmaceuticals Holding Corp, a New York-based clinical-stage biopharmaceutical company, is working to discover, license, acquire and develop small molecules and biologics to treat and prevent human disease.
Its portfolio is primarily made up of central nervous system and immunology product candidates, including vaccines. In the wake of the current pandemic, that has come to include coronavirus (COVID-19) vaccine candidates.
“The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates,” Tonix CEO Seth Lederman said in a recent statement. “We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19.”
This summer, Tonix announced research collaborations with Southern Research and Columbia University to study T-cell and antibody immune responses to the coronavirus in healthy volunteers who have recovered from COVID-19 or were exposed but remain asymptomatic.
Recent TNXP News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/23/2024 09:09:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 11:08:50 AM
- Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) • GlobeNewswire Inc. • 09/23/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/20/2024 09:03:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 11:05:26 AM
- Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines • GlobeNewswire Inc. • 09/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 11:23:27 AM
- Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 11:05:24 AM
- Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:07:15 AM
- Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta • GlobeNewswire Inc. • 09/09/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 09:17:58 PM
- Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:08:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/30/2024 09:04:45 PM
- Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 11:05:17 AM
- Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801 • GlobeNewswire Inc. • 08/26/2024 11:00:00 AM
- Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 11:05:23 AM
- Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication • GlobeNewswire Inc. • 08/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 10:05:58 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM